Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome

QR Code

Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome

Aim. To conduct a comparative analysis of the effect of long-term pharmacotherapy (12 months) using a β-blocker (nebivolol) and its combination with eplerenone in patients after ST-segment elevation acute coronary syndrome (STE-ACS) with heart failure with mildly reduced ejection fraction (EF) (HFmr...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. A. Osipova, V. P. Mikhin, A. I. Golovin, O. N. Belousova, D. N. Perutsky, P. K. Alferov, S. L. Konstantinov
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2022-07-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	st-segment elevation acute coronary syndrome heart failure with mildly reduced ejection fraction nebivolol eplerenone mineralocorticoid receptor antagonist
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/3269
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
by: A. G. Evdokimova, et al.
Published: (2023-01-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
by: N. A. Nuritdinov, et al.
Published: (2020-12-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
by: Yu. M. Lopatin, et al.
Published: (2015-08-01)

Influence of aldosterone antagonists on markers of electrophysiological instability in patients with heart failure with mid-range ejection fraction after ST-segment elevation acute coronary syndrome in the short- and long-term periods
by: L. V. Shekhovtsova, et al.
Published: (2020-11-01)

The use of mineralocorticoid antagonists in chronic heart failure
by: Andrea Szegedi, et al.
Published: (2025-07-01)

New Clinical Aspects of Eplerenone Use in Clinical Practice
by: S. R. Gilyarevskiy, et al.
Published: (2018-09-01)

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
by: A. Yu. Zharikov, et al.
Published: (2021-07-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Electrocardiographic signs of impaired depolarization (fragmented QRS, early ventricular repolarization, etc.) as markers of left ventricular systolic dysfunction
by: M. S. Gordeeva, et al.
Published: (2022-08-01)

URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES
by: M. P. Savenkov, et al.
Published: (2016-01-01)

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]
by: Fei Y, et al.
Published: (2025-06-01)

Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01)

Dynamics of fibrotic and vascular endothelial dysfunction markers in elderly hypertensive patients after ischemic stroke receiving beta-blockers
by: O. A. Osipova, et al.
Published: (2022-01-01)

Prediction model of rehospitalization and mortality in heart failure patients with preserved and mildly reduced ejection fraction: the AD2NNER risk score
by: Flavia-Mihaela Stoiculescu, et al.
Published: (2025-07-01)

Efficacy and Safety of Low‐Dose Spironolactone in Management of Diabetic Kidney Disease in a Real‐World Setting
by: Manochehr Amini, et al.
Published: (2025-07-01)

Possible risk factors for atrial fibrillation in patients with heart failure with mildly reduced ejection fraction
by: L. G. Azarapetyan, et al.
Published: (2024-04-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure
by: Jinyu He, et al.
Published: (2025-07-01)

Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place
by: L. I. Olbinskaya, et al.
Published: (2007-02-01)

THE ROLE OF VASODILATING BETA-BLOCKERS IN PATIENTS WITH HYPERTENSION AND THE CARDIOMETABOLIC SYNDROME
by: A. A. Taylor, et al.
Published: (2011-08-01)

Cardiac remodeling in patients with heart failure with mildly reduced ejection fraction and metabolic disorders: association with biomarkers and autonomic nervous system parameters
by: E. A. Lyasnikova, et al.
Published: (2024-05-01)

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper
by: João Pedro Ferreira, et al.
Published: (2025-08-01)

Effect of β-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction
by: E. V. Grakova, et al.
Published: (2022-04-01)

Left Bundle Branch Area Pacing Prevents New-Onset Atrial Fibrillation and Improves Echocardiographic Parameters Compared with Right Ventricular Pacing in Patients with Bradyarrhythmias
by: Adrian-Ionuț Ungureanu, et al.
Published: (2025-06-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi‐Ethnic Study of Atherosclerosis: The Pooling Project
by: Sarah Nomura, et al.
Published: (2025-06-01)

Biomarkers in the Pathogenesis of Heart Failure with Preserved as Well as Reduced Ejection Fraction: A Cross-sectional Study
by: Sowmiya Thiyagarajan, et al.
Published: (2025-06-01)

EFFICACY AND SAFETY OF VASOACTIVE BETA-BLOCKERS IN ACUTE PHARMACOLOGICAL TEST IN HYPERTENSIVE PATIENTS OF DIFFERENT AGES
by: O. V. Fedorishina, et al.
Published: (2016-01-01)

COMBINED ANTIHYPERTENSIVE THERAPY: ACE INHIBITOR PLUS CALCIUM CHANNEL BLOCKER. NEW ADVANTAGES OF THE KNOWN COMBINATION
by: S. A. Boitsov, et al.
Published: (2016-01-01)

The role of vasodilating β-blockers in controlling arterial hypertension as a means of reducing cardiovascular and stroke risk
by: Jan N. Basile
Published: (2011-06-01)

Dynamics of heart failure markers and cardiac reverse remodeling in patients receiving cardiac contractility modulation therapy
by: M. A. Vander, et al.
Published: (2021-02-01)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

NEBIVOLOL SAFETY AS CARDIOSELECTIVE Β-BLOCKER IN COMPLEX THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE ACCOMPANIED BY CHRONIC OBSTRUCTIVE BRONCHITIS
by: Zh. G. Simonova, et al.
Published: (2003-10-01)